Research ExplorerPublicationsEvaluation of a New Spike (S)-Protein-Based Commercial Immun...

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

Standard

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. / Eberhardt, Kirsten Alexandra; Dewald, Felix; Heger, Eva; Gieselmann, Lutz; Vanshylla, Kanika; Wirtz, Maike; Kleipass, Franziska; Johannis, Wibke; Schommers, Philipp; Gruell, Henning; Brensing, Karl August; Müller, Roman-Ulrich; Augustin, Max; Lehmann, Clara; Koch, Manuel; Klein, Florian; Cristanziano, Veronica Di.

In: MICROORGANISMS, Vol. 9, No. 4, 733, 31.03.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Eberhardt, KA, Dewald, F, Heger, E, Gieselmann, L, Vanshylla, K, Wirtz, M, Kleipass, F, Johannis, W, Schommers, P, Gruell, H, Brensing, KA, Müller, R-U, Augustin, M, Lehmann, C, Koch, M, Klein, F & Cristanziano, VD 2021, 'Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG', MICROORGANISMS, vol. 9, no. 4, 733. https://doi.org/10.3390/microorganisms9040733

APA

Eberhardt, K. A., Dewald, F., Heger, E., Gieselmann, L., Vanshylla, K., Wirtz, M., Kleipass, F., Johannis, W., Schommers, P., Gruell, H., Brensing, K. A., Müller, R-U., Augustin, M., Lehmann, C., Koch, M., Klein, F., & Cristanziano, V. D. (2021). Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. MICROORGANISMS, 9(4), [733]. https://doi.org/10.3390/microorganisms9040733

Vancouver

Eberhardt KA, Dewald F, Heger E, Gieselmann L, Vanshylla K, Wirtz M et al. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. MICROORGANISMS. 2021 Mar 31;9(4). 733. https://doi.org/10.3390/microorganisms9040733

Bibtex

@article{526a08502bc04d1383f1820d12acf01c,
title = "Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG",
abstract = "Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK{\textregistered} anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK{\textregistered} anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON{\textregistered} SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys{\textregistered} anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. Results: Overall, the IDK{\textregistered} anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. Conclusions: The novel IDK{\textregistered} anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic.",
author = "Eberhardt, {Kirsten Alexandra} and Felix Dewald and Eva Heger and Lutz Gieselmann and Kanika Vanshylla and Maike Wirtz and Franziska Kleipass and Wibke Johannis and Philipp Schommers and Henning Gruell and Brensing, {Karl August} and Roman-Ulrich M{\"u}ller and Max Augustin and Clara Lehmann and Manuel Koch and Florian Klein and Cristanziano, {Veronica Di}",
year = "2021",
month = mar,
day = "31",
doi = "10.3390/microorganisms9040733",
language = "English",
volume = "9",
journal = "MICROORGANISMS",
issn = "2076-2607",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

AU - Eberhardt, Kirsten Alexandra

AU - Dewald, Felix

AU - Heger, Eva

AU - Gieselmann, Lutz

AU - Vanshylla, Kanika

AU - Wirtz, Maike

AU - Kleipass, Franziska

AU - Johannis, Wibke

AU - Schommers, Philipp

AU - Gruell, Henning

AU - Brensing, Karl August

AU - Müller, Roman-Ulrich

AU - Augustin, Max

AU - Lehmann, Clara

AU - Koch, Manuel

AU - Klein, Florian

AU - Cristanziano, Veronica Di

PY - 2021/3/31

Y1 - 2021/3/31

N2 - Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys® anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. Results: Overall, the IDK® anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. Conclusions: The novel IDK® anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic.

AB - Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys® anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. Results: Overall, the IDK® anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. Conclusions: The novel IDK® anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic.

UR - https://doi.org/10.3390/microorganisms9040733

U2 - 10.3390/microorganisms9040733

DO - 10.3390/microorganisms9040733

M3 - SCORING: Journal article

C2 - 33807490

VL - 9

JO - MICROORGANISMS

JF - MICROORGANISMS

SN - 2076-2607

IS - 4

M1 - 733

ER -